On Friday, iTeos Therapeutics Inc (ITOS) stock saw a modest uptick, ending the day at $8.81 which represents a slight increase of $0.36 or 4.26% from the prior close of $8.45. The stock opened at ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 4,820,000 shares ...

Officina Stellare S.p.A. (IT:OS) has released an update. Officina Stellare has secured a €1.4 million contract to develop a high-resolution ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

This page features the latest news about the Iteos stock. Iteos Therapeutics stock hits 52-week low at $8.49 Iteos Therapeutics Inc. (NASDAQ: ITOS) stock has reached a 52-week low, touching down ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Roche Holding AG Akt-2.45% CHF213.84B ...